The critical defensive role of mitochochondrial β-oxidation is supported by several preclinical studies that used genetic and pharmacological approaches to modulate CPT1 activity or the activity of the methylation-controlled J protein (MCJ), an inhibitor of Complex I of the ETC, to attenuate NAFLD [124,125]. Here, DNAJC15 is linked to metabolic dysfunction-associated steatotic liver disease.